Phase II study of VELCADE [bortezomib] in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with one prior systemic therapy regimen (X05142)
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Bortezomib (Primary)
- Indications Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- 28 Jul 2009 Actual end date April 2009 added as reported by ClinicalTrials.gov.
- 28 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Nov 2005 New trial record.